Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
about
Regulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservationProteasome inhibitors in progressive renal diseasesAmyloid diseases of the heart: current and future therapiesTargeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategiesBortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosisImmunoglobulin light chain amyloidosis.A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.Recent advances in the management of AL Amyloidosis.A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.Newer Therapies for Amyloid Cardiomyopathy.Bortezomib-induced acute interstitial nephritis.Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.Cardiovascular complications of multiple myeloma in the elderly.Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients
P2860
Q27000202-FD1D69FD-AFF7-46BD-8494-554B58A7B068Q27011485-6362E1A6-92DA-4E28-B804-5DD649627F42Q27023836-A194CA06-7A6B-4F2C-AF90-11A657A8D40BQ27026951-27F31E2C-1871-435F-8BD5-E670E83B1272Q33417805-E5783A33-2797-45F6-A0DB-38FF9E5C11D1Q33427726-B5631FC0-9209-4FCE-89AE-2623B7DCE9A1Q34353682-F5A01292-A8A9-416E-94E3-E608C3E37BB2Q36199790-FCCDB13E-7152-4581-A6C9-16E64A9422E4Q38172295-BCD0EC2D-C445-4FC9-B299-0B21C482D46DQ38411566-254C4C5D-F806-4593-8855-7BEC10BF0243Q38613822-6563F192-5D97-4BE3-B3A8-81A1E0F28EB4Q38807562-1E888E25-EA46-410D-A74F-BE5ACCA6A89CQ38920614-EB8093EF-9105-4F27-B8ED-4724A3B2E39DQ41141007-EA9F2221-E654-46F0-9D70-48A5EC2B4240Q41593651-47A6E204-BB85-490D-973E-7D041E348D9DQ47374630-9A777BF0-6341-4197-A55B-4A3367EC669CQ58029880-71D8B430-246C-480D-9BDF-24E26515157B
P2860
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
description
article
@en
im Juli 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2011
@uk
name
Bortezomib in a phase 1 trial ...... responses and overall effects
@en
Bortezomib in a phase 1 trial ...... responses and overall effects
@nl
type
label
Bortezomib in a phase 1 trial ...... responses and overall effects
@en
Bortezomib in a phase 1 trial ...... responses and overall effects
@nl
prefLabel
Bortezomib in a phase 1 trial ...... responses and overall effects
@en
Bortezomib in a phase 1 trial ...... responses and overall effects
@nl
P2093
P2860
P50
P356
P1476
Bortezomib in a phase 1 trial ...... responses and overall effects
@en
P2093
H Van De Velde
J-P Fermand
L T Heffner
P Ramaswami
R A Vescio
P2860
P304
P356
10.1093/QJMED/HCR105
P407
P577
2011-07-13T00:00:00Z